increased heart rate on tirzepatide Can cause a 10‑bpm increase in resting in a patient titrated from 2.5 mg weekly subcutaneous dosing? Tirzepatide, a dual GIP/GLP1-receptor co-agonist

Remember, weight loss is a gradual process, and slow, steady progress is often the most sustainable and safe approach

Seek support from an expert healthcare provider, nutritionist, or weight management group to address challenges and stay motivated

When readers ask about comparative highlights, many cite the importance of a user-friendly dashboard, a responsive support widget, and tutorials that explain features in plain language

Differences in MACE risk with liraglutide versus placebo between eGFR subgroups in the LEADER CVOT [2] might be coincidental or owing to a specific study population

NEW DELHI: Once relegated to the fringes of lifestyle care, obesity drugs have emerged as one of the world's most powerful growth sectors, ranked by McKinsey alongside AI, EVs and robotics as trillion-dollar opportunities by 2040